The Affiliated Hospital of Chengdu University of Traditional Chinese Medicine
Welcome,         Profile    Billing    Logout  
 0 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Yao, Ping
LUCENT-1, NCT03518086 / 2017-003229-14: An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

Checkmark Full data from P3 LUCENT 1 trial for severe ulcerative colitis
Oct 2022 - Oct 2022: Full data from P3 LUCENT 1 trial for severe ulcerative colitis
Checkmark Efficacy and safety data from LUCENT-1 trial for moderately-to-severely active ulcerative colitis
Feb 2022 - Feb 2022: Efficacy and safety data from LUCENT-1 trial for moderately-to-severely active ulcerative colitis
Checkmark From LUCENT 1 trial for ulcerative colitis
More
Completed
3
1281
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828, Placebo
Eli Lilly and Company
Ulcerative Colitis
01/21
05/24
LUCENT-2, NCT03524092 / 2017-003238-96: A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Checkmark Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis
May 2022 - May 2022: Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis
Checkmark Safety and efficacy data from LUCENT-2 trial for ulcerative colitis
Dec 2021 - Dec 2021: Safety and efficacy data from LUCENT-2 trial for ulcerative colitis
Active, not recruiting
3
1177
Europe, Canada, Japan, US, RoW
Mirikizumab SC, LY3074828, Mirikizumab IV, Placebo SC
Eli Lilly and Company
Ulcerative Colitis
11/21
12/24
NCT03977480: Phase II Study of Hemay007 in Patients With Active Ulcerative Colitis

Terminated
2
70
RoW
Hemay007, Placebo
Tianjin Hemay Pharmaceutical Co., Ltd
Ulcerative Colitis
08/22
08/22
NCT04983043: Efficacy and Safety of QiShen YiQi Dripping Pills in Chronic Heart Failure

Completed
2
228
RoW
Low dose QiShen YiQi Dripping Pills 3 bags, Low dose group, High dose QiShen YiQi Dripping Pills 3 bags, High dose group, QiShen YiQi Dripping Pills placebo 3 bags, Placebo group
Tasly Pharmaceutical Group Co., Ltd
Chronic Heart Failure With Reduced Ejection Fraction
11/24
11/24
Feng, Peimin
NCT06696261: A Study of Lianxiaxiaopi Granules in the Treatment of Postprandial Distress Syndrome

Not yet recruiting
3
342
RoW
Lianxiaxiaopi Granules, a simulated agent of Lianxiaxiaopi Granules
Tasly Pharmaceutical Group Co., Ltd
Postprandial Distress Syndrome
06/26
08/26

Download Options